From the impact of Obamacare to cutting-edge research, biotech buyouts to Big Pharma court battles, The Motley Fool's health-care team sits down each week to discuss the most fascinating developments in health care, and their implications for long-term investors. In this week's edition, the team talks about Novartis' patent dispute, stocks that have both popped and plummeted, and the companies our analysts will be watching in the coming days.
In the following segment, health-care analyst David Williamson discusses two big developments with retail pharmacies that are affecting consumers. Watch and find out why you might be ditching your family doctor for a Walgreen and where you can get the cheapest generic drugs. Fool on!
Costco's low prices haven't just benefited customers -- shares have walloped the market, returning 11,000% over the past two decades. However, with prices near all-time highs, is the ride over for Costco investors? To answer that and more, The Motley Fool's compiled a premium research report with in-depth analysis on Costco. Simply click here now to gain instant access to this valuable investor's resource.